Literature DB >> 27563008

Human galectin-2 interacts with carbohydrates and peptides non-classically: new insight from X-ray crystallography and hemagglutination.

Yunlong Si1, Shiqiong Feng1, Jin Gao1, Yue Wang1, Zhongyu Zhang1, Yue Meng1, Yifa Zhou1, Guihua Tai1, Jiyong Su2.   

Abstract

Galectin-2 (Gal-2) plays a role in cancer, myocardial infarction, immune response, and gastrointestinal tract diseases. The only reported crystal structure of Gal-2 shows that it is a dimer in which the monomer subunits have almost identical structures, each binding with one molecule of lactose. In this study, we crystallized Gal-2 under new conditions that produced three crystal structures. In each Gal-2 dimer structure, lactose was shown to be bound to only one of the carbohydrate recognition domain subunits. In solution studies, the thermal shift assay demonstrated that inequivalent monomer subunits in the Gal-2 dimer become equivalent upon ligand binding. In addition, galectin-mediated erythrocyte agglutination assays using lactose and larger complex polysaccharides as inhibitors showed the structural differences between Gal-1 and Gal-2. Overall, our results reveal some novel aspects to the structural differentiation in Gal-2 and expand the potential for different types of molecular interactions that may be specific to this lectin.
© The Author 2016. Published by Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  carbohydrate recognition domain; hemagglutination assay; human galectin-2 crystal structure

Mesh:

Substances:

Year:  2016        PMID: 27563008     DOI: 10.1093/abbs/gmw089

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  7 in total

1.  Crystallization of Galectin-8 Linker Reveals Intricate Relationship between the N-terminal Tail and the Linker.

Authors:  Yunlong Si; Yue Wang; Jin Gao; Chenyang Song; Shiqiong Feng; Yifa Zhou; Guihua Tai; Jiyong Su
Journal:  Int J Mol Sci       Date:  2016-12-12       Impact factor: 5.923

2.  Galectin-13, a different prototype galectin, does not bind β-galacto-sides and forms dimers via intermolecular disulfide bridges between Cys-136 and Cys-138.

Authors:  Jiyong Su; Yue Wang; Yunlong Si; Jin Gao; Chenyang Song; Linlin Cui; Runjie Wu; Guihua Tai; Yifa Zhou
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

Review 3.  A Brief History of Charcot-Leyden Crystal Protein/Galectin-10 Research.

Authors:  Jiyong Su
Journal:  Molecules       Date:  2018-11-09       Impact factor: 4.411

4.  Resetting the ligand binding site of placental protein 13/galectin-13 recovers its ability to bind lactose.

Authors:  Jiyong Su; Linlin Cui; Yunlong Si; Chenyang Song; Yuying Li; Tong Yang; Hao Wang; Kevin H Mayo; Guihua Tai; Yifa Zhou
Journal:  Biosci Rep       Date:  2018-12-14       Impact factor: 3.840

5.  Stimulation of Collateral Vessel Growth by Inhibition of Galectin 2 in Mice Using a Single-Domain Llama-Derived Antibody.

Authors:  Maurits R Hollander; Matthijs F Jansen; Luuk H G A Hopman; Edward Dolk; Peter M van de Ven; Paul Knaapen; Anton J Horrevoets; Esther Lutgens; Niels van Royen
Journal:  J Am Heart Assoc       Date:  2019-10-09       Impact factor: 5.501

6.  Anti-Galectin-2 Antibody Treatment Reduces Atherosclerotic Plaque Size and Alters Macrophage Polarity.

Authors:  Jamie Kane; Matthijs Jansen; Sebastian Hendrix; Laura A Bosmans; Linda Beckers; Claudia van Tiel; Marion Gijbels; Noam Zelcer; Carlie J de Vries; Philipp von Hundelshausen; Marc Vervloet; Ed Eringa; Anton J Horrevoets; Niels van Royen; Esther Lutgens
Journal:  Thromb Haemost       Date:  2022-02-08       Impact factor: 6.681

Review 7.  Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?

Authors:  Christian Bailly; Xavier Thuru; Bruno Quesnel
Journal:  Cancers (Basel)       Date:  2021-12-18       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.